SkinBioTherapeutics PLC AxisBiotix-Ps(TM) to launch on Amazon UK (1351V)
30 Noviembre 2023 - 1:00AM
UK Regulatory
TIDMSBTX
RNS Number : 1351V
SkinBioTherapeutics PLC
30 November 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
AxisBiotix-Ps(TM) to launch on Amazon UK
30 November 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the
"Company"), the life science business focused on skin health
announces that its AxisBiotix-Ps(TM) food supplement will launch on
Amazon.co.uk from Wednesday, 6 December 2023 at 9am.
The launch of a sales channel through Amazon is a key part of
the commercialisation strategy to expand market share for
AxisBiotix-Ps(TM). The first Amazon launch is in the UK; the aim is
then to extend product availability through other Amazon country
sites. Management is already proactively seeking to expand online
sales of its AxisBiotix-Ps(TM) into the European countries where
the product has regulatory clearance (France, Italy and Spain).
AxisBiotix-Ps(TM) first went on sale to UK in October 2021 and
is intended for customers to alleviate sensitive skin conditions
such as psoriasis. The response from customers continues to be very
positive with the retention rates of AxisBiotix-Ps(TM) in the UK
staying at 80% or above. If access to the product can be made
simpler, via an online channel like Amazon which is familiar to the
majority of people, then management believes this will boost sales
and marketing efforts.
According to Mintel, approximately 90% of the UK adult
population uses Amazon. In 2019 alone, the UK e-commerce market was
the largest in Europe and third largest to China and the US. Amazon
held 30% of this market, and has shown ambitions in the beauty and
skincare markets, with the launch of its own-brand skin care line,
Belei. It has also teamed up with beauty major, L'Oreal.
Stuart J. Ashman, CEO of SkinBioTherapeutics, said : "The skin
care market is a significant market, w ith an increasing global
focus on health and well-being, and the demand for science-backed
supplements is at an all-time high. The primary focus for
AxisBiotix-Ps(TM) is growing our share of the market and using a
sales channel like Amazon, which we use everyday, makes good
strategic sense. We hope to announce the European launches on
Amazon before the end of the year."
-Ends-
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191
Stuart J. Ashman, CEO 495 7325
Manprit Randhawa, CFO
Cavendish Capital Markets Limited Tel: +44 (0) 20 7220
(Nominated Adviser & Broker) 0500
Giles Balleny, Dan Hodkinson (Corporate
Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith (Sales)
Instinctif Partners (financial press) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Jack Kincade 2020
SkinBioTherapeutics@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix(R), is based upon discoveries made by Professor Catherine
O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are
cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin
axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps(TM), a food supplement to address the symptoms
of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information,
visit : www.skinbiotherapeutics.com and www.axisbiotix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PRLDGBDBUXDDGXC
(END) Dow Jones Newswires
November 30, 2023 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024